Hypera (OTCMKTS:HYPMY) Issues Earnings Results

Hypera (OTCMKTS:HYPMY) released its quarterly earnings data on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $258.56 million for the quarter. Hypera had a return on equity of 13.18% and a net margin of 20.04%.

Hypera Stock Up 4.7 %

Hypera stock opened at $3.62 on Friday. Hypera has a one year low of $2.64 and a one year high of $6.90. The business’s fifty day moving average is $3.27 and its 200 day moving average is $3.74. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.